Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Acute Lung Injury

Acute Lung Injury

Part of Acute Respiratory Distress Syndrome

6 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Acute Lung Injury

25 trials tracked for Acute Lung Injury: 3 in phase 3 or 4 and 1 with published results. The most-cited published study has 28 citations.

25Trials tracked
3Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 3 Phase 2 13 Phase 1 1 Other / NA 8
  1. Phase 3 Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure Completed · 28 cited
  2. Phase 3 CALIPSO: Calfactant for Acute Lung Injury in Pediatric Stem Cell Transplant and Oncology Patients Completed
  3. Phase 3 L-citrulline for Prevention of Sequelae of Acute Lung Injury in Pediatrics Undergoing Cardiopulmonary Bypass for Heart Defects Completed
  4. Phase 2 Ascorbic Acid (Vitamin C) Infusion in Human Sepsis Completed
  5. Phase 2 The Safety, Tolerability, PK and PD of GSK2586881 in Patients With Acute Lung Injury Completed
  6. Phase 2 Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury Completed
Show 19 more trials
  1. Phase 2 Hemodynamics and Extravascular Lung Water in Acute Lung Injury Completed
  2. Phase 2 SAFEty Study of Early Infusion of Vitamin C for Treatment of Novel Coronavirus Acute Lung Injury (SAFE EVICT CORONA-ALI) Completed
  3. Phase 2 Safety, Tolerability and Preliminary Efficacy of FP-1201 in ALI and ARDS. Phase I/II Completed
  4. Phase 2 Citrulline in Severe Sepsis Completed
  5. Phase 2 Modulation of Lung Injury Complicating Lung Resection Completed
  6. Phase 2 Study of Enbrel (Etanercept) for the Treatment Sub-Acute Pulmonary Dysfunction After Allogeneic Stem Cell Transplant Completed
  7. Phase 2 Vitamin C Infusion for Treatment in Sepsis Induced Acute Lung Injury Completed
  8. Phase 2 Ganciclovir/Valganciclovir for Prevention of CMV Reactivation in Acute Injury of the Lung and Respiratory Failure Completed
  9. Phase 2 A Phase II Randomized Trial of Fish Oil in Patients With Acute Lung Injury (ALI) Completed
  10. Phase 2 SB-681323 IV for Subjects at Risk of Acute Lung Injury or ARDS Completed
  11. Phase 1 Effects of TNX-832 (Sunol cH36) in Subjects With Acute Lung Injury/Acute Respiratory Distress Syndrome Completed
  12. N/A Effect of Mechanical Ventilation on Plasma Concentration Level of R-spondin Proteins Completed
  13. N/A Extracardiac Complications After Cardiac Surgery Completed
  14. N/A Intensive Alveolar Recruitment Protocol After Cardiac Surgery Completed
  15. N/A The Role of Circulating Soluble CD74 in Acute Lung Injury Completed
  16. N/A Efficacy and Safety of a Lung Recruitment Protocol in Children With Acute Lung Injury Completed
  17. N/A Non-invasive Vagal Neurostimulation (nVNS) for Traumatic Brain Injury (TBI)-Induced Acute Respiratory Distress Completed
  18. N/A the Effect of Dopamine on Mechanical Ventilation Induced Lung Injury Completed
  19. N/A Mechanical Ventilation in the Emergency Department: A Prospective Cross-Sectional Study Completed

Showing the 25 most-cited and recently-updated of 25 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Acute Lung Injury: what the trials found

New evidence indicates that nVNS was associated with zero reported adverse events or serious adverse events up to 30 days from baseline in a small cohort 1.

Aviptadil, administered via intravenous infusion with standard of care, resulted in significantly fewer patients achieving a score of 6-8 on the NIAID Ordinal Score through day 60 compared to the control group (76 vs. 35) and a lower oxygenation index as measured by PaO2:FiO2 ratio (139.2 vs. 116.2) 2.

L-citrulline treatment showed no significant difference in the composite variable of time on mechanical ventilation or inotrope use compared to control (p=0.1560), but was associated with a statistically significant improvement in hemodynamic status as measured by central venous pressure (p=0.0326) 3.

Calfactant administration resulted in significantly fewer ventilator-free days compared to the control group (0 vs. 5.40) 4.

Ascorbic acid was evaluated in multiple studies; one trial showed a reduction in modified change in Sequential Organ Failure Assessment (mSOFA) scores and observed specific levels of C-reactive protein and thrombomodulin protein 7, while another study confirmed its use as an intervention 15.

Mechanical ventilation is established as a standard intervention, with studies identifying correlations between the duration of mechanical ventilation and DRD1 expression (r = -0.555, p<0.01) [20, 21].

Recent results — preliminary, needs further review

  • nVNS: No adverse events or serious adverse events reported within 30 days 1.

For the clinician treating this condition

  • Aviptadil is associated with lower rates of achieving target NIAID Ordinal Scores and lower PaO2:FiO2 ratios compared to standard care.
  • L-citrulline may improve central venous pressure, though it did not significantly impact the duration of mechanical ventilation or inotrope use.
  • Calfactant was associated with a reduction in ventilator-free days.
  • Mechanical ventilation duration correlates significantly with DRD1 expression.

AI synthesis of 6 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Adrenergic receptor signaling modulates pulmonary innate immunity and barrier integrity in acute lung injury
Diabetes & Endocrinology Sys. Review
Adrenergic receptor signaling modulates pulmonary innate immunity and barrier integrity in acute lung injury Understanding How Nerve Signals Influence Lung Health During Severe Respiratory Infections
This systematic review synthesizes the role of adrenergic receptors (ARs) as a molecular interface between the sympathetic nervous system an…
New research explores how specific nerve signals help control inflammation and protect the lungs during severe lung infections.
Frontiers Jul 10, 2026
Review discusses metabolic reprogramming of macrophages for sepsis-associated acute lung injury with noted limitations
Allergy & Immunology Sys. Review
Review discusses metabolic reprogramming of macrophages for sepsis-associated acute lung injury with noted limitations Immune Cell Energy Switch Offers Hope Against Deadly Sepsis Lungs
This narrative review examines the concept of metabolic reprogramming of macrophages as a potential approach for sepsis-associated acute lun…
• Scientists reprogrammed immune cells to calm sepsis lung damage • Helps critically ill patients with few current options • Still in lab te…
Frontiers May 15, 2026
Intravenous Recombinant Human Plasma Gelsolin Safety and Pharmacokinetics Evaluated in Phase 1 Trial of Healthy Volunteers
Drug Pipeline RCT
Intravenous Recombinant Human Plasma Gelsolin Safety and Pharmacokinetics Evaluated in Phase 1 Trial of Healthy Volunteers Can this new IV drug be safely given? Early results show mild effects
This Phase 1 randomized controlled trial evaluated the safety and pharmacokinetics of intravenous recombinant human plasma gelsolin in 32 he…
A new IV drug caused only mild side effects in healthy volunteers, but doctors must wait for more data before using it to treat sick patient…
medRxiv Apr 19, 2026
Review of preclinical EVs for sepsis-associated acute lung injury
Pulmonology & Critical Care Sys. Review
Review of preclinical EVs for sepsis-associated acute lung injury Lungs Heal Themselves Using Body’s Own Repair System
This narrative review examines extracellular vesicles (EVs) and EV-inspired biomimetic nanosystems as a potential therapeutic approach for…
Tiny cell bubbles calm deadly lung inflammation in sepsis, offering a new way to help the body fix its own lungs during severe infections.
Frontiers Apr 18, 2026
Systematic review examines miRNA-mediated neutrophil regulation for acute lung injury, asthma, fibrosis, and lung cancer
Allergy & Immunology Sys. Review
Systematic review examines miRNA-mediated neutrophil regulation for acute lung injury, asthma, fibrosis, and lung cancer Tiny Molecules in Your Blood May Control Lung Inflammation
This systematic review evaluated miRNA-mediated regulation of neutrophil dynamics as a potential therapeutic strategy for acute lung injury,…
Tiny molecules in your blood act as a switch that controls the immune cells causing lung damage in asthma, fibrosis, and cancer.
Frontiers Apr 14, 2026
Outbreak report summarizes patterns and characteristics of vaping-associated lung injury cases
Infectious Disease
Outbreak report summarizes patterns and characteristics of vaping-associated lung injury cases What did we learn from the vaping lung injury outbreak?
An observational outbreak report summarized patterns and characteristics of lung injury cases associated with e-cigarette use across multipl…
A 2019 wave of serious lung injuries swept across the United States, and all the cases had one thing in common: the people affected had used…
CDC Apr 6, 2026

Questions about Acute Lung Injury

Can biomimetic nanosystems be used to treat sepsis-induced acute lung injury?

Biomimetic nanosystems inspired by extracellular vesicles are being studied as a promising way to balance immune responses and treat sepsis-induced acute lung injury.

Full answer →
What are the common patterns in vaping-associated acute lung injury cases?

Vaping-associated acute lung injury is often linked to products containing cannabinoids and frequently presents with patterns like diffuse alveolar damage or organizing pneumonia.

Full answer →
Is recombinant human plasma gelsolin safe to use for acute lung injury?

Recombinant human plasma gelsolin (rhu-pGSN) was found to be safe and well-tolerated in a Phase 1 trial involving healthy volunteers.

Full answer →
Does miRNA regulation of neutrophils help treat acute lung injury?

Research suggests that microRNAs (miRNAs) can regulate neutrophil behavior and may offer a promising way to treat acute lung injury, though most evidence currently comes from preclinical studies.

Full answer →
Are extracellular vesicles a potential treatment for sepsis-related acute lung injury?

Extracellular vesicles show potential as both a contributor and a therapeutic target in sepsis-related acute lung injury, but clinical use is still experimental.

Full answer →
See all 5 questions about Acute Lung Injury →